在神经胶质瘤组织中的表达及其临床意义

  目的  探讨神经胶质瘤组织中CCNG2的表达，其表达状况与临床病理参数的相关性及意义。  方法  收集2007年1月至2012年8月在本院手术切除的神经胶质瘤组织标本129例。采用QRT-PCR及免疫组织化学染色方法，在基因及蛋白水平检测其中临床资料完整的109例神经胶质瘤标本中CCNG2的表达。  结果  在109例神经胶质瘤组织标本中，CCNG2在高级别的神经胶质瘤组织中的表达较低级别的明显降低，其表达与肿瘤的分级呈负相关，差异具有统计学意义（P < 0.05）。CCNG2的表达与患者性别、年龄无关（均P>0.05）；而与肿瘤的分级、对放化疗的敏感性及总生存时间相关（均P < 0.001）。  结论  检测CCNG2的表达有助于阐释神经胶质瘤发生发展的机制，并可作为评估神经胶质瘤恶性生物学行为及预后的参考指标。 

Expression and clinical significance of CCNG2 in glioblastoma patients

  Object  To investigate the expression of cell cyclin G2 (CCNG2) in glioblastoma tissues and to explore the correlation of CCNG2 expression with clinicopathological parameters and clinical significance.  Methods  Surgical specimens of glioblastoma were collected from a total of 129 cases. The expression of CCNG2 in 109 specimens with complete clinical data was examined via QRT-PCR and immunohistochemistry.  Results  The expression of CCNG2 was significantly decreased in higher stages of glioblastoma compared with those in lower stages. Therefore, CCNG2 is inversely correlated with the stage of the disease. The expression of CCNG2 was associated with tumor stage, sensitivity to chemotherapy and radiotherapy, as well as survival times (P < 0.05). CCGN2 was not correlated with gender and age (P>0.05).  Conclusion  CCNG2 expression may be associated with the development, treatment efficacy, and prognosis of glioblastoma. In addition, CCGN2 can be used to evaluate the malignant behavior of glioblastoma.